BSGM needs top spot on your radar once again this morning.

SmallCapFirm

Key Details Now: Wednesday AM Complete Update On Nasdaq Profile (BSGM)

August 31st

SCF Readers,

BSGM needs top spot on your radar once again this morning.

Yesterday, the company dropped some big news that needs to be read. Check it out: BioSig Strengthens Marketing and Sales Teams, Appoints National Account Executives to Scale Commercial Growth

From the article:

... The Company appointed a new team of National Account Executives who will be strategically located throughout the U.S. to support and accelerate sales growth and adoption of the PURE EP™ System...

Long story short, BSGM is ramping up to become a nationwide force.

But how many people have caught hold of this news yet? Doesn't look like many.

Furthermore, BSGM also held above two lines of potential support in its 50-Day Simple Moving Average (SMA) and its 13-Day Exponential Moving Average (EMA).

Even though BSGM closed in the red on Tuesday, the fact that those lines held strong could mean big things ahead for this Nasdaq idea.

Factor in BSGM's TipRanks reported analyst target and its 200-Day SMA, and there could be a bunch of potential upside from current trading levels.

Read more key BSGM details below from my initial report.

-----

Hot on the tracks of another breakout idea, I've been tracking a past champ with great focus based on several factors.

One key factor is this: Similar to KULR, this past champ has moved above both its 50-Day SMA and 13-Day EMA in the last few weeks while putting together multiple green closes in August.

Plus, with a $4.00 analyst price target being reported by TipRanks,

image

... it could be trading from undervalued levels like when it was brought to your attention in May and ran approximately 15% intraday.

Factor in a slew of other breakout movers over the previous two months:

16%, 14%, 26%, 24%, 24%, 53%, 33%, 18%,

and it's easy to see we've been hot and it's no time to slow down now.

BioSig Technologies, Inc. (BSGM)

BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals.

And right now, BSGM has multiple potential catalysts that could spark a near term vertical move. Check them out:

#1. BSGM Potential Catalyst - Company CEO Makes Major BSGM Share Purchases

Wow. To say BSGM CEO, Kenneth Londoner, went "hard in the paint" last week might be an understatement.

Over the span of 3 days, the company's CEO purchased thousands of shares.

What does he know that we don't? Could something big be right around the corner?

Check out his spending spree:

#1. 8/16/22 (25,100 shares)

#2. 8/17/22 (13,100 shares)

#3. 8/19/22 (10,000 shares)

All I'm going to say is, "Hmmmm."

-----

#2. BSGM Potential Catalyst - Positive Momentum Spotted In Company's Sales Pipeline Growth

BioSig Sees Positive Momentum from Sales Pipeline Growth

Westport, CT, Aug. 16, 2022 (GLOBE NEWSWIRE) --

  • Company sees increase in medical centers entering into 60-day evaluation agreements
  • Existing customers seeing positive results from PURE EP™ System expected to increase number of units purchased

BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company"), a medical technology company advancing electrophysiology workflow by delivering greater intracardiac signal fidelity through its proprietary signal processing platform, today announced that it is seeing positive momentum from the growth of its sales pipeline, and expects to see an increase in enterprise adoption of its PURE EP™ System in the coming months.

Since BioSig’s national commercial launch of its PURE EP™ System on July 1st, 2022, the Company’s commercial pipeline has experienced a steady increase in advanced leads and technology adoption across several key regions and centers of excellence...

...

The demand for minimally invasive catheter-based ablation procedures continues to grow. We believe that market demand is high, and expect to see an acceleration of commercial activity in our quarterly results going forward,” commented Kenneth L. Londoner, Chairman and CEO of BioSig Technologies, Inc.

BioSig’s commercial momentum is supported by its recent decision to streamline the PURE EP™ System evaluation period from 180-360 days to 60-days. The Company has also implemented a new leasing program to help expedite the acquisition of Pure EP’s superior signal processing capabilities and shortens the sales cycle. Consistent with its stated commercial strategy, BioSig is prioritizing the growth of its robust sales team, including the recent appointment of a new sales leader who will cover the COLT states (Colorado, Oklahoma, Louisiana, and Texas).

By shortening our evaluation period and providing flexible paths to purchase, we are meeting the demands of physicians and supply chain management, ensuring that superior signal processing technology is within reach. We’re pleased to be exploring opportunities for repeat business and additional unit placement with many of our existing accounts,” commented Gray Fleming, Chief Commercialization Officer, BioSig Technologies, Inc.

Read the full article here.

-----

#3. BSGM Potential Catalyst - Milestone Achievement Reached With New Purchase Agreement

BioSig Announces Purchase Agreement with Kansas City Heart Rhythm Institute at Overland Park Regional Medical Center

Westport, CT, July 07, 2022 (GLOBE NEWSWIRE) --

  • OPRMC marks our first leasing agreement under new program
  • Company also inks national master agreement with one of the largest U.S. healthcare systems

BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company"), a medical technology company advancing electrophysiology workflow by delivering greater intracardiac signal fidelity through its proprietary signal processing platform, today announced that Kansas City Heart Institute at Overland Park Regional Medical Center in Kansas City, U.S. has signed a purchase agreement to acquire its PURE EP(T.M.) System.

Following its evaluation of BioSig's PURE EP(T.M.) System, Overland Park Regional Medical Center (OPRMC) has signed an agreement to purchase the technology under the terms of the Company's new program. The agreement represents BioSig's first commercial adoption since it announced the national launch of its PURE EP ™ System, supported by The Company's new commercial structure and clinical support teams. The agreement also represents The Company's first national purchasing agreement.

"Establishing a contract with a leading national hospital network is a milestone achievement for BioSig Technologies," commented Gray Fleming, Chief Commercialization Officer, BioSig Technologies, Inc. "A leasing option provides a cost-effective and efficient pathway for hospitals to acquire our technology. As a Company that prioritizes physician experience and throughput, we believe a leasing program supports the clinical evolution of PURE EP as we continue upgrading and enhancing our technology based on physician feedback."

...

Read the full article here.

-----

#4. BSGM Potential Catalyst - Company Enters Into Key Evaluation Agreement With The Cleveland Clinic

BioSig Announces New Evaluation Agreement for its PURE EP System with Cleveland Clinic

Leading Center of Excellence will participate in a 60-day evaluation of The Company’s signal processing technology

Westport, CT, June 22, 2022 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) a medical technology company advancing electrophysiology workflow by delivering greater intracardiac signal fidelity through its proprietary signal processing platform, today announced it has entered an evaluation agreement for its PURE EP(TM) System with the Cleveland Clinic.

The evaluation agreement marks the first since BioSig inducted a new commercialization team. Consistent with The Company’s stated national rollout strategy, Cleveland Clinic will participate in a 60-day evaluation of BioSig’s PURE EP(TM) System. The Company recently announced that is has restructured its clinical support and installation teams to streamline and accelerate the pathway from product evaluation to adoption.

We are excited to include Cleveland Clinic as an evaluation center for the Pure EP System. We look forward to working alongside their physicians to demonstrate the superior signal quality that can be achieved on even the most difficult arrhythmias,” commented Gray Fleming, Chief Commercialization Officer, BioSig Technologies, Inc.

...

Read the full article here.

-----

#5. BSGM Potential Catalyst - Another Low Float Profile

According to the Yahoo Finance website, BSGM has a relatively low float.

The website reports this profile to have approximately 40.02Mn shares in its float.

Why is that important? It's important on one crucial level. Volatility.

With so few shares available for trading, other potential catalysts (like big news) could spark a vertical move in the short-term.

-----

BSGM Recap - Key Potential Catalysts To Know Right Now

#1. - Company CEO Makes Major BSGM Share Purchases

#2. - Positive Momentum Spotted In Company's Sales Pipeline Growth

#3. - Milestone Achievement Reached With New Purchase Agreement

#4. - Company Enters Into Key Evaluation Agreement With The Cleveland Clinic

#5. - Another Low Float Profile

-----

Coverage is officially initiated on BSGM. When you have time later, do this:

image

Get BSGM on your radar now.

Sincerely,

Axel Adams

Editor, SCF


Source 1


(Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)​

image
image